These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 3073772)
1. Beneficial effects of a thromboxane receptor antagonist (BM 13.505) on platelet hyperreactivity and thromboxane formation in cholesterol-fed rabbits. Löbel P; Schrör E; Schrör K Biomed Biochim Acta; 1988; 47(10-11):S86-9. PubMed ID: 3073772 [TBL] [Abstract][Full Text] [Related]
2. Investigations of the antiatherosclerotic effect of the thromboxane A2 receptor antagonist Daltroban. Pill J; Wolf O; Schmelz A; Stegmeier K; Metz J Z Kardiol; 1990; 79 Suppl 3():155-60. PubMed ID: 2151550 [TBL] [Abstract][Full Text] [Related]
3. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo. Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979 [TBL] [Abstract][Full Text] [Related]
4. Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits. Osborne JA; Lefer AM Am J Physiol; 1988 Aug; 255(2 Pt 2):H318-24. PubMed ID: 2970233 [TBL] [Abstract][Full Text] [Related]
5. Oral naftidrofuryl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemic rabbits. Weber AA; Hohlfeld T; Strobach H; Schrör K J Cardiovasc Pharmacol; 1993 Feb; 21(2):332-8. PubMed ID: 7679170 [TBL] [Abstract][Full Text] [Related]
6. Atherosclerosis in the aorta of hypercholesterolemic rabbits and the influence of daltroban. Metz J; Wolf O; Schmelz A; Pill J; Stegmeier KH; Hartig F Exp Pathol; 1991; 41(2):57-69. PubMed ID: 1828033 [TBL] [Abstract][Full Text] [Related]
7. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate. Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011 [TBL] [Abstract][Full Text] [Related]
8. Effects of daltroban, a thromboxane (TX) A2 receptor antagonist, on lipid metabolism and atherosclerosis. Pill J; Metz J; Stegmeier K; Hartig F Agents Actions Suppl; 1992; 37():107-13. PubMed ID: 1632287 [TBL] [Abstract][Full Text] [Related]
9. ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca++ concentrations. Bretschneider E; Glusa E; Schrör K Thromb Res; 1994 Aug; 75(3):233-42. PubMed ID: 7992234 [TBL] [Abstract][Full Text] [Related]
10. Changes in platelet reactivity, prostacyclin and thromboxane production after long-term oral defibrotide in healthy and atherosclerotic rabbits. Löbel P; Palmér M; Schrör K Prog Clin Biol Res; 1987; 242():265-70. PubMed ID: 3313414 [No Abstract] [Full Text] [Related]
11. Stimulation of vascular prostacyclin and inhibition of platelet function by oral defibrotide in cholesterol-fed rabbits. Löbel P; Schrör K Atherosclerosis; 1989 Nov; 80(1):69-79. PubMed ID: 2513813 [TBL] [Abstract][Full Text] [Related]
12. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Schrör K; Löbel P; Steinhagen-Thiessen E Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819 [TBL] [Abstract][Full Text] [Related]
13. ADP-induced second wave aggregation in platelet rich plasma from hypercholesterolemic rabbits. Weber A; Hohlfeld T; Schrör K Thromb Res; 1991 Dec; 64(6):703-12. PubMed ID: 1798959 [TBL] [Abstract][Full Text] [Related]
14. Shortening of platelet survival by induced hypercholesterolaemia in rabbits and its prolongation by anagrelide. Barrett PA; Butler KD Thromb Haemost; 1983 Oct; 50(3):656-9. PubMed ID: 6648889 [TBL] [Abstract][Full Text] [Related]
15. The thromboxane receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis. Thiemermann C; Ney P; Schrör K Eur J Pharmacol; 1988 Oct; 155(1-2):57-67. PubMed ID: 2977337 [TBL] [Abstract][Full Text] [Related]
16. Effects of dipyridamole in experimental atherosclerosis. Action on PGI2, platelet aggregation and atherosclerotic plaque formation. Dembińska-Kièć A; Rücker W; Schönhöfer PS Atherosclerosis; 1979 Jul; 33(3):315-27. PubMed ID: 226106 [TBL] [Abstract][Full Text] [Related]
17. Effects of chronic administration of ethanol on platelets from rabbits with diet-induced hypercholesterolemia. Unchanged characteristics and responses to ADP but reduction of enhanced thrombin-induced, TxA2-independent platelet responses. Latta EK; Packham MA; DaCosta SM; Rand ML Arterioscler Thromb; 1994 Aug; 14(8):1372-7. PubMed ID: 8049200 [TBL] [Abstract][Full Text] [Related]
18. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death. Lefer DJ; Mentley RK; Lefer AM Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969 [TBL] [Abstract][Full Text] [Related]
19. Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. Hohlfeld T; Scharnowski F; Braun M; Schrör K Thromb Haemost; 1994 Jan; 71(1):112-8. PubMed ID: 7513092 [TBL] [Abstract][Full Text] [Related]
20. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides. Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]